Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Epilepsy Behav. 2003 Dec;4(6):710-6.

Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy.

Author information

  • 1Centre for Health Services Research, University of Newcastle upon Tyne, Newcastle upon Tyne, UK.

Abstract

OBJECTIVE:

The goal of our work was to assess compliance and patient satisfaction with switching from sodium valproate to Depakine Chrono in patients with epilepsy.

METHODS:

Clinical, demographic, and behavioral details assessing compliance and satisfaction were collected using self-completion questionnaires at the time of inclusion in the study and 3 months after the inclusion day.

RESULTS:

Data were collected from 2031 respondents from eight European countries. There were significant differences between time 1 and time 2 of the study in seizure frequency, reported side effects, compliance, and patient satisfaction.

CONCLUSION:

Findings suggest that switching from sodium valproate to Depakine Chrono results in an increase in seizure-free rates, a reduction in reported side effects, an improvement in the level of compliance, and a modest improvement in patient satisfaction.

PMID:
14698705
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk